Open Access
Access granted
Subscription or Fee Access
No 2 (2015)
- Year: 2015
- Articles: 14
- URL: https://journals.eco-vector.com/2412-4036/issue/view/6626
Articles
Uvazhaemye kollegi!
Therapy. 2015;(2):2-2
2-2
European Federation of Internal Medicine: on the path to European Congress of Internal Medicine’2015 in Moscow
Therapy. 2015;(2):4-7
4-7
VI all-Russian scientific-practical conference with international participation «Topical issues of internal pathology. Connective tissue dysplasia»
Therapy. 2015;(2):8-8
8-8
National guidelines for the diagnosis and treatment of acid-related and associated with Helicobacter pylori diseases (V Moscow agreement)
Therapy. 2015;(2):9-18
9-18
ROLE OF ENDOTOXIN OF INTESTINAL MICROBIOTA IN THE PATHOGENESIS OF ATHEROSCLEROSIS
Abstract
Recent data on the processes that underlie atherogenesis, indicate a significant role of endotoxin in the gut development of vascular lesions. The paper summarizes the materials of literature and the results of their research on pathways of participation and lipopolysaccharide (endotoxin) of gramnegative bacteria in the initiation and progression of atherosclerosis. Endotoxin can activate all the cells involved in the formation of atherosclerotic plaques, cause the transformation of macrophages in the arterial intima foam cells, endothelial damage and induce hyperlipidemia. A better understanding of the mechanisms of formation of atherosclerotic lesions may help in the development of new treatment options and disease prevention.
Therapy. 2015;(2):19-27
19-27
THE INFLUENCE OF ACID-SUPPRESSIVE THERAPY ON THE CLINICAL COURSE OF ISCHEMIC HEART DISEASE WITH REFRACTORY PAIN SYNDROME IN THE CHEST
Abstract
Frequent comorbid coronary heart disease (CHD) and gastroesophageal reflux disease (GERD) are defined by the presence of their common risk factors, relaxing the influence of a number of drugs for the treatment of coronary artery disease in the smooth muscles of the lower esophageal sphincter, as well as the ability to reflux during stimulation of the esophageal mucosa to cause reflex cardiac disorders including coronary artery spasm, and arrhythmia. Resistance chest pain to antianginal drugs may also be due to its non-coronary origin, including those associated with GERD. Appointment of proton pump inhibitors can not only restore the normal pH values of intraesophageal non-coronary arrest and chest pain caused by GERD, but also reduce the number and severity of episodes of pain associated with myocardial ischemia, which improves the clinical course of comorbid disease and improves the quality of life of patients. Rabeprazole (Pariet) has a number of positive characteristics that provide high speed of onset of effect, a weak dependence on the genetic polymorphism of liver enzymes, and minimal risk of drug-drug interactions, including drugs for the treatment of coronary artery disease, including clopidogrel.
Therapy. 2015;(2):28-36
28-36
DRUG METABOLISM IN PATIENTS WITH LIVER DISEASES
Abstract
The article highlights the issues of drug metabolism in patients with various liver diseases, presents pathophysiological mechanisms of disorders of biotransformation of substances depending on the severity of hepatocytes, names the reasons for drug interactions of pharmacological agents, which leads to an undesirable increase in the concentration of drug in the blood, strengthening and lengthening of the therapeutic effect with increased the risk of side effects.
Therapy. 2015;(2):37-42
37-42
TACTICS OF THERAPY IN ACUTE INTESTINAL INFECTIONS
Abstract
The review presents the modern methods of diagnosis and treatment of acute intestinal infections. Detailed methods of clinical diagnosis, clinical and laboratory examination, recommendations on causal, pathogenetic and symptomatic therapy are presented. An overview of the main groups of drugs recommended at each stage of treatment is given.
Therapy. 2015;(2):43-55
43-55
ESSENTsIAL'NYE FOSFOLIPIDY: OT FARMAKOLOGIChESKIKh SVOYSTV K TERAPEVTIChESKOMU EFFEKTU
Abstract
Liver damages caused by different etiological agents are a common cause of morbidity and mortality in the population, so their treatment is one of the most actual problems of modern medicine. Positive hepatotropic impact of essential phospholipids (EPL) is known for more than 100 years, more than 50 years apply commercial drugs based on EPL, which effectiveness is proven in numerous clinical and experimental studies. Because of the ability to be embedded into a damaged cell membranes of hepatocytes EPL contribute to the restoration and preservation of the cellular structure of the liver and enzyme activity of hepatocytes, improve metabolism of neutral fats and cholesterol, protein metabolism, detoxification, stabilization function of physico-chemical properties of bile, slowing down the formation of connective tissue and the development of fibrosis.
Therapy. 2015;(2):56-63
56-63
SINDROM RAZDRAZhENNOGO KIShEChNIKA: MOZhNO LI DOSTICh' EFFEKTA MINIMAL'NYM LEKARSTVENNYM VOZDEYSTVIEM?
Abstract
The article presents current data on the mechanisms of pathogenesis and clinical variants of irritable bowel syndrome (IBS). Particular attention is given to an inflammation in the genesis of the disease. It was stressed that IBS is now seen not as a purely functional disorder, but as inflammation of the intestine with minimal changes in the mucous membrane. In this regard, it justified to use of a complex preparation of Kolofort, which has a positive impact on the development of the basic mechanisms and clinical symptoms of IBS. Comprehensive action is observed due to its three components: affinity-purified release-active brain-specific proteins with antibodies to S-100, histamine and tumor necrosis factor a. The results of a multicenter double-blind placebo-controlled randomized clinical studies have shown that Kolofort has a pronounced analgesic effect in patients with all types of IBS, which developed during the first 2 weeks of therapy. It was found that a decrease in the severity of abdominal pain syndrome and restore the motor-evacuation function of the gastrointestinal tract during treatment with Kolofort was due to the impact of both the central and the peripheral pathogenesis of IBS, visceral hypersensitivity and hyperalgesia, subclinical inflammation and physiological disorders.
Therapy. 2015;(2):64-71
64-71
APPLICATIONS OF REMAXOL IN HEPATOTOXIC LESIONS
Abstract
Modern management of patients with hepatotoxic lesions based on the principle of an integrated approach to treatment. One of the main measures, along with the most rapid and intensive detoxification is to correct metabolic disorders and prevention of severe complications. Appointment of drugs that reduce the degree of metabolic disorders in these cases is of paramount importance. Use of the drug Remaxol (solution for infusion), possessing hepatoprotective, anti-hypoxic, antioxidant and cytoprotective effects in the complex pathogenetic therapy of patients with liver disease significantly reduces the severity of clinical manifestations and cytolytic and cholestatic syndromes. In clinical studies, and the subsequent application in actual practice shows good tolerability and Remaxol (frequency of adverse events that required discontinuation of therapy did not exceed 0.3%).
Therapy. 2015;(2):72-79
72-79
ZAPOR: ChTO DOLZhEN ZNAT' VRACh OBShchEY PRAKTIKI?
Abstract
The article presents an analysis of the results of recent research on the effectiveness of different groups of pharmacological agents in the treatment of constipation. Authors consider criteria for the diagnosis of chronic functional constipation, present classification of laxatives depending on the mechanism of action and the results of a meta-analysis of the clinical effectiveness of various groups of laxatives.
Therapy. 2015;(2):80-86
80-86
To the 80th birthday of Boris Yakovlevich Bart
Therapy. 2015;(2):87-87
87-87
Viktor Maksimovich Yakovlev (1924-2015)
Therapy. 2015;(2):88-88
88-88